BASKING RIDGE, N.J., April 16, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the closing of its previously announced underwritten public offering. The gross proceeds to Regado from its sale of 10,000,000 shares of common stock at a price to the public of $6.00 per share were approximately $60.0 million, prior to deducting underwriting discounts and commissions and other offering expenses payable by Regado.
Regado expects to use the net proceeds of this offering to fund further clinical development of its lead product candidate, REG1, and for working capital and other general corporate purposes.
Jefferies LLC, Deutsche Bank Securities and Cowen and Company, LLC, acted as joint book-running managers for the proposed offering.
A registration statement on Form S-1 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission and is effective. The final prospectus related to the offering also has been filed with the SEC. Copies of the final prospectus and the accompanying prospectus may be obtained from the offices of Jefferies LLC, c/o Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY, 10022, or by emailing [email protected], or by telephone at (877) 547-6340, or from the offices of Deutsche Bank Securities Inc., c/o Prospectus Group, 60 Wall Street, New York, NY 10005, or by emailing [email protected] or by telephone at (800) 503-4611, or from the offices of Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Prospectus Department, or by telephone at (631) 274-2806.
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc. is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs. More information can be found at www.regadobio.com.
For more information on REGULATE-PCI, please visit: http://www.clinicaltrials.gov/ct2/show/NCT01848106
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the anticipated use of proceeds from the offering. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from those projected in forward-looking statements include the "Risk Factors" described in the prospectus included in Regado's Registration Statement on Form S-1 (File No. 333-195005), initially filed with the SEC on April 3, 2014, and as amended. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company has no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contacts:
Tricia Truehart or Chelsea Wheeler
SOURCE Regado Biosciences, Inc.